A double-blind, randomized, placebo-controlled study assessing polarity-analysis-guided individualized homeopathic therapy for chronic primary heel pain in adults.
Description
This double-blind, randomized, placebo-controlled trial (n=74, 2:1 allocation) evaluated polarity analysis-guided individualized homeopathic medicines (IHMs) versus placebo over 3 months in adults with chronic primary heel pain, using Foot Function Index (FFI) total score as primary outcome and MYMOP-2 as secondary, revealing monotonic FFI improvement in IHMs versus flat placebo trajectories (FDA divergence by week 3; p<0.001), placebo ending 29.9 points higher (GEE; p<0.001), 100% Bayesian superiority probability (slope difference 16.06), 100% responder rates (MCID ≥7; OR=741, NNT=1.1; AUC difference -96.7; p<0.001), robust across subgroups/sensitivity analyses via MLMM/GEE, confirming PA-guided IHMs as safe, rapidly effective therapy warranting larger confirmatory trials.